Is Buying Cascadian Therapeutics Inc (NASDAQ:CASC), Having Lower Short Interest a Winning Strategy?

April 1, 2018 - By Vivian Currie

The stock of Cascadian Therapeutics Inc (NASDAQ:CASC) registered a decrease of 20.61% in short interest. CASC’s total short interest was 650,100 shares in April as published by FINRA. Its down 20.61% from 818,900 shares, reported previously. With 2.14 million shares average volume, it will take short sellers 0 days to cover their CASC’s short positions. The short interest to Cascadian Therapeutics Inc’s float is 2.46%.

It closed at $10.02 lastly. It is down 0.00% since April 1, 2017 and is . It has underperformed by 11.55% the S&P500.

Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company has market cap of $529.41 million. The firm lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It currently has negative earnings. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: